Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
34
SEER Quote, Financials, Valuation and Earnings
Last price:
$1.92
Seasonality move
:
-20.82%
Day range:
$1.77 - $1.92
52-week range:
$1.62 - $2.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.81x
P/B ratio:
0.40x
Volume:
1.2M
Avg. volume:
194.3K
1-year change:
-15.49%
Market cap:
$107.4M
Revenue:
$13.9M
EPS (TTM):
-$1.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
$4.6M | -$0.32 | 7.02% | -4.23% | $3.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$230.8M | -$0.37 | -87.58% | -73.49% | $81.67 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
$1.91 | $3.00 | $107.4M | -- | $0.00 | 0% | 6.81x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.47 | $31.21 | $3.8B | 14.46x | $0.00 | 0% | 3.61x |
|
AGEN
Agenus, Inc.
|
$2.98 | $12.33 | $101.3M | -- | $0.00 | 0% | 0.75x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$322.28 | $479.79 | $42.6B | 1,340.04x | $0.00 | 0% | 13.22x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$61.55 | $81.67 | $8.6B | 40.01x | $0.00 | 0% | 7.76x |
|
SVRA
Savara, Inc.
|
$5.35 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
8.19% | 1.747 | 20.03% | 13.50x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 3.853 | 7.54% | 3.27x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
$2.1M | -$19.3M | -23.75% | -25.71% | -469.45% | -$7.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Seer, Inc. (California) vs. Competitors
-
Which has Higher Returns SEER or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -442.47% compared to Seer, Inc. (California)'s net margin of 25.76%. Seer, Inc. (California)'s return on equity of -25.71% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.2% -$0.32 $296.1M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SEER or ACAD?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 57.07%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 38.9%. Given that Seer, Inc. (California) has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Seer, Inc. (California) is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SEER or ACAD More Risky?
Seer, Inc. (California) has a beta of 1.634, which suggesting that the stock is 63.415% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock SEER or ACAD?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or ACAD?
Seer, Inc. (California) quarterly revenues are $4.1M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Seer, Inc. (California)'s net income of -$18.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.81x versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.81x -- $4.1M -$18.2M ACADACADIA Pharmaceuticals, Inc.3.61x 14.46x $278.6M $71.8M
-
Which has Higher Returns SEER or AGEN?
Agenus, Inc. has a net margin of -442.47% compared to Seer, Inc. (California)'s net margin of -116.82%. Seer, Inc. (California)'s return on equity of -25.71% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.2% -$0.32 $296.1M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About SEER or AGEN?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 57.07%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 313.87%. Given that Agenus, Inc. has higher upside potential than Seer, Inc. (California), analysts believe Agenus, Inc. is more attractive than Seer, Inc. (California).
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 AGENAgenus, Inc.2 1 0 -
Is SEER or AGEN More Risky?
Seer, Inc. (California) has a beta of 1.634, which suggesting that the stock is 63.415% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock SEER or AGEN?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or AGEN?
Seer, Inc. (California) quarterly revenues are $4.1M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Seer, Inc. (California)'s net income of -$18.2M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.81x versus 0.75x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.81x -- $4.1M -$18.2M AGENAgenus, Inc.0.75x -- $30.2M $63.9M
-
Which has Higher Returns SEER or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -442.47% compared to Seer, Inc. (California)'s net margin of 20.1%. Seer, Inc. (California)'s return on equity of -25.71% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.2% -$0.32 $296.1M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About SEER or ALNY?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 57.07%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 48.87%. Given that Seer, Inc. (California) has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Seer, Inc. (California) is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is SEER or ALNY More Risky?
Seer, Inc. (California) has a beta of 1.634, which suggesting that the stock is 63.415% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock SEER or ALNY?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or ALNY?
Seer, Inc. (California) quarterly revenues are $4.1M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Seer, Inc. (California)'s net income of -$18.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,340.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.81x versus 13.22x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.81x -- $4.1M -$18.2M ALNYAlnylam Pharmaceuticals, Inc.13.22x 1,340.04x $1.2B $251.1M
-
Which has Higher Returns SEER or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -442.47% compared to Seer, Inc. (California)'s net margin of 10.7%. Seer, Inc. (California)'s return on equity of -25.71% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.2% -$0.32 $296.1M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About SEER or ARWR?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 57.07%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.67 which suggests that it could grow by 32.68%. Given that Seer, Inc. (California) has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Seer, Inc. (California) is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 4 0 -
Is SEER or ARWR More Risky?
Seer, Inc. (California) has a beta of 1.634, which suggesting that the stock is 63.415% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.339%.
-
Which is a Better Dividend Stock SEER or ARWR?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or ARWR?
Seer, Inc. (California) quarterly revenues are $4.1M, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Seer, Inc. (California)'s net income of -$18.2M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 40.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.81x versus 7.76x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.81x -- $4.1M -$18.2M ARWRArrowhead Pharmaceuticals, Inc.7.76x 40.01x $264M $28.2M
-
Which has Higher Returns SEER or SVRA?
Savara, Inc. has a net margin of -442.47% compared to Seer, Inc. (California)'s net margin of --. Seer, Inc. (California)'s return on equity of -25.71% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.2% -$0.32 $296.1M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SEER or SVRA?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 57.07%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 102.1%. Given that Savara, Inc. has higher upside potential than Seer, Inc. (California), analysts believe Savara, Inc. is more attractive than Seer, Inc. (California).
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 SVRASavara, Inc.6 0 0 -
Is SEER or SVRA More Risky?
Seer, Inc. (California) has a beta of 1.634, which suggesting that the stock is 63.415% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock SEER or SVRA?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or SVRA?
Seer, Inc. (California) quarterly revenues are $4.1M, which are larger than Savara, Inc. quarterly revenues of --. Seer, Inc. (California)'s net income of -$18.2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.81x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.81x -- $4.1M -$18.2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
